Trial Profile
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Vactosertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023.